Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cancer of the Prostate: full-pipeline trial registry
5 of 12 indexed Cancer of the Prostate trials are currently recruiting.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 5 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Cancer of the Prostate: 12 US clinical trials tracked, 5 recruiting.
Cancer of the Prostate is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Urological Research Network, running 2 of these trials.
Enrollment posture brief
Registry condition cancer-of-the-prostate
OPEN 5 | RECR 42% | LATE 2 | EARLY 2 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adiposity (42% recruiting · 12 trials)
Cancer of the Prostate lists 5 open slots (42% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cancer of the Prostate on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cancer of the Prostate is recruiting below its size-band peers.
5 of 12 indexed trials (41.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Cancer of the Prostate research.
Urological Research Network accounts for 2 of 12 trials (16.7%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Cancer of the Prostate enrolment sits around 1,000 participants.
Median target enrolment is 1,000 among the 12 trials that report a genuine target (sentinel values excluded). 3 of those (25%) plan for fewer than 100 participants.
-
Cancer of the Prostate research is mostly interventional.
9 interventional and 3 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Washington University School of Medicine
NCT07109427
MRI/Ultrasound Fusion Guided Prostate Cryotherapy
Urological Research Network
NCT02381990
MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer
Urological Research Network
NCT05241236
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Pfizer
NCT07028853
Investigation of Impact of AI on Prostate Cancer Workflow
Case Comprehensive Cancer Center
NCT07084779
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer
NCT02319837
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
Washington University School of Medicine
NCT05628363
Proton Boost in Prostate Cancer
University of Cincinnati
NCT03564275
North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)
UNC Lineberger Comprehensive Cancer Center
NCT02564120
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Accuray Incorporated
NCT00643617
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
Progenics Pharmaceuticals
NCT03939689
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
Infinity Pharmaceuticals
NCT00564928
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Cancer of the Prostate records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cancer of the Prostate trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cancer of the Prostate page
12 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Cancer of the Prostate trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Urological Research Network sponsors the most Cancer of the Prostate trials on record, review their full trial history before evaluating a specific study. See Urological Research Network's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cancer of the Prostate condition card totals 12 registered trials; most-linked intervention Enzalutamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.